Explore how Low Dose Naltrexone may target inflammaging and support healthspan, based on real-world findings from 5,500 participants.
Category: AgelessRx Research
Explore how Microdosing Semaglutide may support metabolic health, inflammation, and longevity, including what our GLP-1 trial is studying.
Curious about the SF-36 quality of life study? Discover what this validated health survey measures and what our longevity research found.
Fat intake, gut microbiome composition, and enzyme activity may all influence Rapamycin absorption. See what our study revealed.
Explore PEARL trial findings on Rapamycin, Low Dose Naltrexone, and bone density, including a notable case report, potential mechanisms, safety considerations, and the need for larger clinical studies.
Low Dose Naltrexone and NAD+ were tested together for Long COVID fatigue in our trial. Learn what the results showed and why the combination worked.
Our Research Team tracked Acarbose as a longevity intervention in a pilot trial. See biomarker findings, glucose data, and tolerability results.
A closer look at our Canagliflozin pilot trial, including the study design, metabolic findings, glucose response, and tolerability in healthy adults.
AgelessRx shares early XPRIZE Healthspan semifinal results and what they suggest about the future of personalized longevity medicine.
AgelessRx is an XPRIZE Healthspan semifinalist! Learn more about the AgelessRx XPRIZE trial and what this means for the future of aging.
Discover the results of PEARL trial, straight from the AgelessRx experts who led the study, and learn what this means for the future of Rapamycin.